Natural and Designed Cyclic Peptides as Potential Antiviral Drugs to Combat Future Coronavirus Outbreaks

Area of Science:

• Virology
• Medicinal Chemistry
• Drug Discovery

Background:

• The COVID-19 pandemic revealed critical gaps in antiviral drug development, particularly for RNA viruses.
• Increased human-animal interactions drive the emergence of novel viral threats, necessitating robust therapeutic strategies.
• Current antiviral treatments are often costly and lack broad-spectrum efficacy, creating a need for accessible alternatives.

Purpose of the Study:

• To review the urgent need for effective and affordable antiviral drugs, especially against RNA viruses.
• To highlight cyclic peptides as a promising class of compounds for developing broad-spectrum antiviral therapies.
• To emphasize the potential of cyclic peptides in combating future pandemic threats.

Main Methods:

• Literature review focusing on antiviral drug development and the properties of cyclic peptides.
• Analysis of RNA virus characteristics, including mutation rates and resistance mechanisms.
• Evaluation of cyclic peptides derived from natural sources and designed via molecular modeling for antiviral potential.

Main Results:

• RNA viruses present significant challenges due to rapid mutation, high transmissibility, and immune evasion.
• A scarcity of broad-spectrum antiviral drugs and the high cost of existing treatments necessitate new solutions.
• Cyclic peptides demonstrate favorable attributes such as stability, low toxicity, high target specificity, and reduced resistance.

Conclusions:

• Cyclic peptides represent a sustainable and viable approach to developing novel antiviral medications.
• Further research into cyclic peptides is crucial for addressing unmet needs in antiviral drug discovery and pandemic preparedness.
• These compounds offer a potential new strategy to combat RNA viruses and mitigate future public health crises.